Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
LINGO-1 negatively regulates myelination by oligodendrocytes.
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.
MS Research Roundup: February 5, 2014
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Gordon Research Conference: Myelin
MS Research Roundup: January 9, 2014
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
MS Patient, Ph.D.: Setting the Right Expectations for Recovery
Roche’s ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
Foreseeing the Future?
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
Autoimmunity's next top models.
CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier.
Episode 63 with Dr. Helen Tremlett on studying sun exposure in MS
iConquerMS™ Advances Patient-Driven Multiple Sclerosis Research
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
Low testosterone is associated with disability in men with multiple sclerosis.

Pages